論文 - 石田　悠志

Paediatric anaplastic large‐cell lymphoma with cardiac tamponade 査読

Takahiro Shiwaku, Kosuke Tamefusa, Hisashi Ishida, Kaori Fujiwara, Kana Washio, Hirokazu Tsukahara

2025年4月

　詳細を見る

掲載種別：研究論文（学術雑誌）  

DOI： 10.1111/bjh.19980

researchmap

Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era 査読

Toshihide Yoshikawa, Hisashi Ishida, Akihiro Watanabe, Yuki Yuza, Haruko Shima, Masaki Ito, Yukari Sakurai, Dai Keino, Takuya Ichimura, Keisuke Kato, Yuko Osugi, Shosuke Sunami, Kunihiro Shinoda, Toshihiko Imamura, Katsuyoshi Koh, Yuri Okimoto, Chikako Tono, Hiroyuki Shimada, Akihiko Tanizawa

International Journal of Hematology   2025年3月

　詳細を見る

担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1007/s12185-025-03953-x

researchmap

その他リンク： https://link.springer.com/article/10.1007/s12185-025-03953-x/fulltext.html

Empowering pediatric, adolescent, and young adult patients with cancer utilizing generative AI chatbots to reduce psychological burden and enhance treatment engagement: a pilot study 査読

Joe Hasei, Mana Hanzawa, Akihito Nagano, Naoko Maeda, Shinichirou Yoshida, Makoto Endo, Nobuhiko Yokoyama, Motoharu Ochi, Hisashi Ishida, Hideki Katayama, Tomohiro Fujiwara, Eiji Nakata, Ryuichi Nakahara, Toshiyuki Kunisada, Hirokazu Tsukahara, Toshifumi Ozaki

Frontiers in Digital Health   7   2025年2月

　詳細を見る

掲載種別：研究論文（学術雑誌）  

DOI： 10.3389/fdgth.2025.1543543

researchmap

Alectinib maintenance therapy following cord blood transplantation for relapsed pediatric anaplastic large cell lymphoma with central nervous system involvement 査読

Kosuke Tamefusa, Hisashi Ishida, Daisuke Miyahara, Takahiro Shiwaku, Motoharu Ochi, Kiichiro Kanamitsu, Kaori Fujiwara, Yasuhisa Tatebe, Kana Washio, Tomoyuki Akiyama, Hirokazu Tsukahara

Annals of Hematology   2024年11月

　詳細を見る

掲載種別：研究論文（学術雑誌）  

DOI： 10.1007/s00277-024-06000-7

researchmap

Letermovir at a Prophylactic Dose for Cytomegalovirus Infection in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study in Japan 査読

Yasuhisa Tatebe, Yohei Manabe, Yuta Tanaka, Takahiro Shiwaku, Motoharu Ochi, Kosuke Tamefusa, Hisashi Ishida, Kaori Fujiwara, Kana Washio, Hirofumi Hamano, Kiminaka Murakawa, Yoshito Zamami

Biological and Pharmaceutical Bulletin   47 ( 9 )   1575 - 1582   2024年9月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1248/bpb.b24-00217

researchmap

Salvage hematopoietic cell transplantation for children with acute myeloid leukemia relapsed after first transplantation: a Japanese national registry study 査読

Hirotoshi Sakaguchi, Takashi Taga, Hisashi Ishida, Asahito Hama, Yasuhiro Okamoto, Hideki Sano, Maho Sato, Yuhki Koga, Katsuyoshi Koh, Fuminori Iwasaki, Nao Yoshida, Yuko Cho, Keiko Okada, Kentaro Watanabe, Akihiro Watanabe, Daiichiro Hasegawa, Maiko Noguchi, Yoshiko Hashii, Kimikazu Matsumoto, Ken Tabuchi, Daisuke Tomizawa, Yuichi Mitani, Soichi Adachi, Shotaro Iwamoto, Yuta Kawahara, Akira Shimada, Yasuko Kojima, Shinichi Tsujimoto, Takako Miyamura, Shohei Yamamoto, Ayako Yamamori, Masanori Yoshida

Bone Marrow Transplantation   2024年8月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1038/s41409-024-02396-y

researchmap

その他リンク： https://www.nature.com/articles/s41409-024-02396-y

Utilizing the Metaverse to Provide Innovative Psychosocial Support for Pediatric, Adolescent, and Young Adult Patients with Rare Cancer 査読

Joe Hasei, Hisashi Ishida, Hideki Katayama, Naoko Maeda, Akihito Nagano, Motoharu Ochi, Masako Okamura, Shintaro Iwata, Kunihiro Ikuta, Shinichirou Yoshida, Tomohiro Fujiwara, Eiji Nakata, Ryuichi Nakahara, Toshiyuki Kunisada, Toshifumi Ozaki

Cancers   16 ( 15 )   2617 - 2617   2024年7月

　詳細を見る

掲載種別：研究論文（学術雑誌）  

DOI： 10.3390/cancers16152617

researchmap

Differential impact of asparaginase discontinuation on outcomes of children with T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma 査読

Hisashi Ishida, Toshihiko Imamura, Ryoji Kobayashi, Yoshiko Hashii, Takao Deguchi, Takako Miyamura, Megumi Oda, Masaki Yamamoto, Keiko Okada, Hideki Sano, Katsuyoshi Koh, Yuki Yuza, Kenichiro Watanabe, Noriyuki Nishimura, Tetsuya Takimoto, Akiko Moriya‐Saito, Masahiro Sekimizu, Souichi Suenobu, Shosuke Sunami, Keizo Horibe

Cancer Medicine   13 ( 12 )   2024年6月

　詳細を見る

担当区分：筆頭著者   掲載種別：研究論文（学術雑誌）  

DOI： 10.1002/cam4.7246

researchmap

Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells. 査読 国際誌

Joana Carrelha, Stefania Mazzi, Axel Winroth, Michael Hagemann-Jensen, Christoph Ziegenhain, Kari Högstrand, Masafumi Seki, Margs S Brennan, Madeleine Lehander, Bishan Wu, Yiran Meng, Ellen Markljung, Ruggiero Norfo, Hisashi Ishida, Karin Belander Strålin, Francesca Grasso, Christina Simoglou Karali, Affaf Aliouat, Amy Hillen, Edwin Chari, Kimberly Siletti, Supat Thongjuea, Adam J Mead, Sten Linnarsson, Claus Nerlov, Rickard Sandberg, Tetsuichi Yoshizato, Petter S Woll, Sten Eirik W Jacobsen

Nature Immunology   25 ( 6 )   1007 - 1019   2024年6月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1038/s41590-024-01845-6

PubMed

researchmap

Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single‐center, retrospective study 査読

Kosuke Tamefusa, Motoharu Ochi, Hisashi Ishida, Takahiro Shiwaku, Kiichiro Kanamitsu, Kaori Fujiwara, Yasuhisa Tatebe, Naomi Matsumoto, Kana Washio, Hirokazu Tsukahara

European Journal of Haematology   112 ( 5 )   714 - 722   2024年5月

　詳細を見る

掲載種別：研究論文（学術雑誌）  

DOI： 10.1111/ejh.14162

researchmap

A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemia 査読

Hisashi Ishida, Yuta Kawahara, Daisuke Tomizawa, Yasuhiro Okamoto, Asahito Hama, Yuko Cho, Katsuyoshi Koh, Yuhki Koga, Nao Yoshida, Maho Sato, Kiminori Terui, Naoyuki Miyagawa, Akihiro Watanabe, Junko Takita, Ryoji Kobayashi, Masaki Yamamoto, Kenichiro Watanabe, Keiko Okada, Koji Kato, Kimikazu Matsumoto, Moeko Hino, Ken Tabuchi, Hirotoshi Sakaguchi

Journal of Hematology & Oncology   17 ( 24 )   2024年4月

　詳細を見る

担当区分：筆頭著者,　責任著者  

DOI： 10.1186/s13045-024-01548-3.

researchmap

Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia 査読

Hisashi Ishida, Yuki Arakawa, Daiichiro Hasegawa, Ikuya Usami, Yoshiko Hashii, Yasuyuki Arai, Satoshi Nishiwaki, Dai Keino, Keisuke Kato, Maho Sato, Nao Yoshida, Yukiyasu Ozawa, Keiko Okada, Moe Hidaka, Yuki Yuza, Masatsugu Tanaka, Kenichiro Watanabe, Junko Takita, Yoshiyuki Kosaka, Naoto Fujita, Junji Tanaka, Atsushi Sato, Yoshiko Atsuta, Toshihiko Imamura

Annals of Hematology   103 ( 3 )   843 - 854   2024年

　詳細を見る

担当区分：筆頭著者   掲載種別：研究論文（学術雑誌）  

DOI： 10.1007/s00277-023-05557-z

PubMed

researchmap

その他リンク： https://link.springer.com/article/10.1007/s00277-023-05557-z/fulltext.html

造血細胞移植後の肝障害の鑑別にMRIが有用であった輸血後鉄過剰症の2小児例 査読

鷲尾 佳奈, 塩飽 孝宏, 爲房 宏輔, 越智 元春, 石田 悠志, 金光 喜一郎, 藤原 かおり, 塚原 宏一

日本輸血細胞治療学会誌   69 ( 5 )   605 - 609   2023年10月

　詳細を見る

記述言語：日本語   出版者・発行元：一般社団法人 日本輸血・細胞治療学会  

小児がん患者における輸血後鉄過剰症については，海外からは報告が散見される．成人と同様，白血病等における同種造血細胞移植患者において，移植前の血清フェリチン値と合併症の相関等が議論されているが，日本国内からはまだまとまった報告はない．我々は，肝障害を来し，輸血後鉄過剰症と肝移植片対宿主病（GVHD）との鑑別に磁気共鳴画像（MRI）が有用であった2例を経験した．2例とも急性骨髄性白血病であり，肝GVHDとして免疫抑制療法等を行ったにもかかわらず遷延する肝障害を呈していた．高フェリチン血症を認めたためMRI撮像したところ，高度鉄沈着を示唆する所見を呈した．輸血後鉄過剰症として鉄キレート療法を行って肝障害が改善した．小児がん患者において，骨髄抑制期間が長く頻回の輸血を要するような症例では，急性期に臓器障害を伴う輸血後鉄過剰症を示す可能性があるが，治療介入の指針や時期については明らかになっていない．今後日本国内でも大規模な調査が必要と思われる．

DOI： 10.3925/jjtc.69.605

researchmap

A Boy Safely Treated with Tyrosine Kinase Inhibitors for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Osteolysis. 査読

Takahiro Shiwaku, Hisashi Ishida, Yasuhisa Tatebe, Kosuke Tamefusa, Motoharu Ochi, Kaori Fujiwara, Toshihide Kubo, Eiji Nakata, Kana Washio, Hirokazu Tsukahara

Acta medica Okayama   77 ( 4 )   439 - 442   2023年8月

　詳細を見る

担当区分：責任著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

A three-year-old boy with Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ALL) presented with an osteolytic lesion in his right upper arm. Tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib are an essential component throughout the course of treatment for Ph+ALL. However, TKIs are reported to affect the bone metabolism. In the treatment course of the current patient, the osteolytic lesion quickly improved despite the continuous use of TKIs, even during the concomitant use of corticosteroids. This suggests that TKIs can be safely given with concomitant corticosteroids to children with Ph+ALL, even when osteolytic lesions are present.

DOI： 10.18926/AMO/65757

PubMed

researchmap

Optimizing transplantation procedures through identification of prognostic factors in second remission for children with acute myeloid leukemia with no prior history of transplant 査読

Hisashi Ishida, Shin-ichi Tsujimoto, Daisuke Hasegawa, Hirotoshi Sakaguchi, Shohei Yamamoto, Masakatsu Yanagimachi, Katsuyoshi Koh, Akihiro Watanabe, Asahito Hama, Yuko Cho, Kenichiro Watanabe, Maiko Noguchi, Masanobu Takeuchi, Junko Takita, Kana Washio, Keisuke Kato, Takashi Koike, Yoshiko Hashii, Ken Tabuchi, Moeko Hino, Yoshiko Atsuta, Yasuhiro Okamoto

Haematologica   109 ( 1 )   312 - 317   2023年7月

　詳細を見る

担当区分：筆頭著者,　責任著者   掲載種別：研究論文（学術雑誌）  

DOI： 10.3324/haematol.2023.283203

PubMed

researchmap

Outcome of hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia not in remission enrolled in JACLS ALL-02. 査読

Mio Yano, Hisashi Ishida, Junichi Hara, Hiroshi Kawaguchi, Etsuro Ito, Akiko Moriya-Saito, Yoshiko Hashii, Takao Deguchi, Takako Miyamura, Atsushi Sato, Hiroki Hori, Keizo Horibe, Toshihiko Imamura

International journal of hematology   118 ( 3 )   364 - 373   2023年6月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Hematopoietic stem cell transplantation (HSCT) is only indicated for acute lymphoblastic leukemia (ALL) patients for whom other treatments are unlikely to be curative. However, outcomes of patients not in complete remission (CR) at HSCT remain very poor. To improve the outcomes of patients receiving HSCT, it is important to obtain detailed clinical information about patients with ALL receiving HSCT in CR and not in CR. Patients enrolled in the Japan Association of Childhood Leukemia Study ALL-02 who underwent HSCT and were not in CR (non-CR patients, n = 55) were examined. The 1-year overall survival (OS) rate of non-CR patients was 27.3%. Compared with CR patients, non-CR patients experienced very early and early relapse significantly more frequently and had poorer prognostic factors. Most interestingly, high hyperdiploid (HHD) patients showed an excellent 1-year OS of 80%. In addition, long-term survival among surviving HHD patients was longer than 5 years. All eight patients who survived after undergoing HSCT while not in CR were younger than 10 years at initial diagnosis and were negative for central nervous system involvement. While limited, these results suggest that a subset of patients may benefit from HSCT while not in CR.

DOI： 10.1007/s12185-023-03626-7

PubMed

researchmap

Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era. 査読 国際誌

Hisashi Ishida, Hiroyuki Shimada, Akihiko Tanizawa, Yutaka Shimazu, Takayoshi Tachibana, Noriko Doki, Takahide Ara, Yayoi Matsuo, Miho Nara, Tomomi Toubai, Kazuko Ino, Hirohisa Nakamae, Keisuke Kato, Koji Kato, Atsushi Sato, Moeko Hino, Kimikazu Matsumoto, Yoshiko Atsuta, Masahiro Yasui, Tokiko Nagamura-Inoue

American journal of hematology   98 ( 8 )   E200 - E203   2023年5月

　詳細を見る

担当区分：筆頭著者,　責任著者   記述言語：英語  

DOI： 10.1002/ajh.26959

PubMed

researchmap

Three Cases of Down Syndrome with Transient Abnormal Myelopoiesis who Underwent Liver Biopsy before Induction of Low-Dose Cytarabine. 査読

Kana Washio, Kosuke Tamefusa, Motoharu Ochi, Kiichiro Kanamitsu, Hisashi Ishida, Kaori Fujiwara, Kenji Nishida, Kei Tamai, Yosuke Washio, Junko Yoshimoto, Takuo Noda, Hirokazu Tsukahara

Acta medica Okayama   77 ( 2 )   215 - 220   2023年4月

　詳細を見る

記述言語：英語  

Among patients with transient abnormal myelopoiesis (TAM) associated with Down syndrome, approximately 20% die within 6 months from multiorgan failure, especially liver fibrosis. We experienced three children with TAM who had low white blood cell counts but increased bilirubin levels. Here, we discuss the detailed clinical courses of these patients, including the pathological findings of liver biopsies. Our cases, together with previous literature, suggest that liver biopsy can be performed safely and provides useful information, especially regarding disease activities, and that low-dose cytarabine is a reasonable option to prevent early death in TAM patients with liver dysfunction.

DOI： 10.18926/AMO/65153

PubMed

researchmap

Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL-02 protocol. 査読 国際誌

Hisashi Ishida, Toshihiko Imamura, Yasuhisa Tatebe, Takashi Ishihara, Kimiyoshi Sakaguchi, Souichi Suenobu, Atsushi Sato, Yoshiko Hashii, Takao Deguchi, Yoshihiro Takahashi, Daiichiro Hasegawa, Takako Miyamura, Akihiro Iguchi, Koji Kato, Akiko Saito-Moriya, Junichi Hara, Keizo Horibe

British journal of haematology   201 ( 6 )   1200 - 1208   2023年3月

　詳細を見る

担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

Asparaginase is an essential drug for acute lymphoblastic leukaemia (ALL) treatment, but has several side effects, and its discontinuation often compromises patient outcomes. In the prospective Japan Association of Childhood Leukaemia Study ALL-02 protocol, two major changes were made: (1) additional chemotherapies to compensate for the reduction of treatment intensity when asparaginase was discontinued and (2) more intensive concomitant corticosteroid administration, relative to our previous ALL-97 protocol. In ALL-02 study, 1192 patients were included and L-asparaginase was discontinued for 88 (7.4%). Discontinuation due to allergy was markedly decreased relative to the ALL-97 protocol (2.3% vs 15.4%). Event-free survival (EFS) among patients with T-ALL was compromised when L-asparaginase was discontinued, as well as among patients with high-risk B-cell ALL, especially when discontinued before maintenance therapy. Moreover, multivariate analysis identified discontinuation of L-asparaginase as an independent poor prognostic factor for EFS. In the current study, additional chemotherapies failed to fully compensate for L-asparaginase discontinuation, illustrating the difficulty of replacing asparaginase with other classes of drugs, although this study was not designed to evaluate the effect of these modifications. Concomitant intensive corticosteroid treatment may help to reduce allergy to asparaginase. These results will assist in further optimization of asparaginase use.

DOI： 10.1111/bjh.18745

PubMed

researchmap

Posttransplant gilteritinib maintenance therapy for pediatric acute myeloid leukemia with myelodysplasia-related changes with FLT3-internal tandem duplication. 査読 国際誌

Kosuke Tamefusa, Hisashi Ishida, Kiichiro Kanamitsu, Motoharu Ochi, Kaori Fujiwara, Yasuhisa Tatebe, Michinori Aoe, Seishiro Nodomi, Kana Washio

Pediatric blood & cancer   70 ( 4 )   e30108   2022年12月

　詳細を見る

記述言語：英語  

DOI： 10.1002/pbc.30108

PubMed

researchmap

Low‐dose acyclovir for prophylaxis of varicella‐zoster virus reactivation after hematopoietic stem cell transplantation in children 査読 国際誌

Yasuhisa Tatebe, Soichiro Ushio, Satoru Esumi, Hikaru Sada, Motoharu Ochi, Kosuke Tamefusa, Hisashi Ishida, Kaori Fujiwara, Kiichiro Kanamitsu, Kana Washio, Risa Katsube, Kiminaka Murakawa, Yoshito Zamami

Pediatric Blood & Cancer   69 ( 12 )   e29979   2022年9月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

BACKGROUND: Varicella-zoster virus (VZV) reactivation is a serious complication of hematopoietic stem cell transplantation (HSCT). Although low-dose acyclovir can prevent VZV reactivation after HSCT in adults, the efficacy of a dose of acyclovir lower than the recommended dose, such as 60-80 mg/kg/day in children, is unclear. In this study, we aimed to evaluate the incidence of VZV reactivation after HSCT during and after low-dose acyclovir administration for preventing VZV reactivation in children. METHODS: This single-center retrospective study included children aged ≤15 years who received oral acyclovir (at 15 mg/kg/day) to prevent VZV reactivation after HSCT. We examined the cumulative incidence of VZV reactivation after HSCT, during and after prophylactic acyclovir administration. RESULTS: Fifty-three eligible patients were included in this study, of whom 37 underwent allogeneic HSCT. The median duration of prophylactic acyclovir therapy was 264 days (range: 69-1140 days). VZV reactivation occurred in 13 patients (24.5%, 95% confidence interval [CI]: 14.9-37.6). The cumulative incidence of VZV reactivation 1 and 2 years after HSCT was 6.26% (95% CI: 1.60-15.5) and 20.9% (95% CI: 10.3-34.0), respectively. While only one patient developed VZV reactivation during the administration of prophylactic acyclovir, the cumulative incidence of VZV reactivation increased to 24.2% (95% CI: 12.5-38.0) 1 year after the cessation of acyclovir. CONCLUSION: Low-dose acyclovir (15 mg/kg/day) could be effective for preventing VZV reactivation after HSCT in children because VZV reactivation seldom occurs during the administration of 15 mg/kg/day acyclovir.

DOI： 10.1002/pbc.29979

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/pbc.29979

Prognostic factors of children and adolescents with T‐cell acute lymphoblastic leukemia after allogeneic transplantation 査読 国際誌

Hisashi Ishida, Motohiro Kato, Yuta Kawahara, Sae Ishimaru, Yuho Najima, Shinichi Kako, Maho Sato, Mitsuteru Hiwatari, Maiko Noguchi, Keisuke Kato, Katsuyoshi Koh, Keiko Okada, Fuminori Iwasaki, Ryoji Kobayashi, Shunji Igarashi, Shoji Saito, Yoshiyuki Takahashi, Atsushi Sato, Junji Tanaka, Yoshiko Hashii, Yoshiko Atsuta, Hirotoshi Sakaguchi, Toshihiko Imamura

Hematological Oncology   40 ( 3 )   457 - 468   2022年8月

　詳細を見る

担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

Acute lymphoblastic leukemia (ALL) is the most common cancer during childhood, and some high-risk patients with ALL require hematopoietic stem cell transplantation (HSCT). Mainly due to small patient numbers, studies focusing specifically on children and adolescents with T-cell ALL (T-ALL) are limited. Using a nationwide registry, we retrospectively analyzed data from patients under 20 years old who underwent their first HSCT for T-ALL between 2000 and 2018. As a result, total 484 patients were included, and their median follow-up period was 6.9 years after HSCT for survivors. While patients receiving HSCT at first complete remission (CR) showed relatively good 5-year leukemia free survival (5yLFS, 73.5%), once relapse occurred, their prognosis was much worse (44.4%) even if they attained second remission again (p < 0.001). Among patients receiving HSCT at CR1, grade II-IV acute graft versus host disease was associated with worse overall and LFS than grade 0-I (5yLFS 69.5% vs. 82.1%, p = 0.026) mainly due to high non-relapse mortality. Among those patients, patients receiving related bone marrow transplantation, unrelated bone marrow transplantation, or unrelated cord blood transplantation showed similar survival (5yLFS, 73.2%, 76.3%, and 77.0%, respectively). For patients undergoing cord blood transplantation at CR1, total-body irradiation-based myeloablative conditioning was associated with better 5yLFS than other conditioning regimens (85.4% vs. 62.2%, p = 0.044), as it reduced the risk of relapse. These results indicate that relapsed patients have much less chance of cure, and that identifying patients who require HSCT for cure and offering them HSCT with optimal settings during CR1 are crucial for children and adolescents with T-ALL.

DOI： 10.1002/hon.2980

PubMed

researchmap

Low <scp>NUDT15</scp> expression levels due to biallelic <scp> NUDT15 </scp> variants and 6‐mercaptopurine intolerance 査読 国際誌

Masanori Yoshida, Scott A. Brown, Takaya Moriyama, Rina Nishii, Shin‐ichi Tsujimoto, Yuji Yamada, Kaoru Yoshida, Ryota Shirai, Tomoo Osumi, Tomoyuki Utano, Reiji Fukano, Ko Kudo, Kimiyoshi Sakaguchi, Yuki Arakawa, Katsuyoshi Koh, Masahiro Sekiguchi, Masahiro Sekimizu, Takako Miyamura, Hisashi Ishida, Takeshi Inukai, Daisuke Tomizawa, Nobutaka Kiyokawa, Motohiro Kato, Jun J. Yang

British Journal of Haematology   199 ( 2 )   270 - 276   2022年7月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

6-Mercaptopurine (6-MP) is widely used for the treatment of paediatric leukaemia and lymphoma. Recently, germline variants in the NUDT15 gene have been identified as one of the major genetic causes for 6-MP-associated adverse effects such as myelosuppression. Patients with hypomorphic NUDT15 variants accumulate excessive levels of DNA-incorporated thioguanine in white blood cells, resulting in severe myelosuppression. Although preclinical studies suggest that these variants may influence the protein stability of NUDT15, this has not been directly characterised in patients. In this study, we report the development of a series of novel monoclonal antibodies against NUDT15, using which we quantitatively assessed NUDT15 protein levels in 37 patients with acute lymphoblastic leukaemia treated with 6-MP, using sandwich enzyme-linked immunosorbent assay (ELISA). The NUDT15 genotype was highly correlated with its protein levels (p < 0.0001), with homozygous and compound heterozygous patients showing exceedingly low NUDT15 expression. There was a positive correlation between NUDT15 protein level and 6-MP tolerance (r = 0.631, p < 0.0001). In conclusion, our results point to low NUDT15 protein abundance as the biochemical basis for NUDT15-mediated 6-MP intolerance, thus providing a phenotypic readout of inherited NUDT15 deficiency.

DOI： 10.1111/bjh.18375

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bjh.18375

Impact of KIR-ligand mismatch on pediatric T-cell acute lymphoblastic leukemia in unrelated cord blood transplantation 査読 国際誌

Yuta Kawahara, Sae Ishimaru, Junji Tanaka, Shinichi Kako, Masahiro Hirayama, Minoru Kanaya, Hisashi Ishida, Maho Sato, Ryoji Kobayashi, Motohiro Kato, Kumiko Goi, Shoji Saito, Yuhki Koga, Yoshiko Hashii, Koji Kato, Atsushi Sato, Yoshiko Atsuta, Hirotoshi Sakaguchi

Transplantation and Cellular Therapy   28 ( 9 )   598.e1-598.e8   2022年6月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Currently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered to be indicated for children and adolescents with high-risk or relapsed T-cell acute lymphoblastic leukemia (T-ALL); however, the outcomes are unsatisfactory. Killer cell immunoglobulin-like receptors (KIRs) are the main receptors on natural killer (NK) cells that play an important role in the graft-versus-leukemia effect after allo-HSCT. In allo-HSCT, when the recipient lacks a donor KIR-ligand (KIR-ligand mismatch in the graft-versus-host [GVH] direction), donor NK cells will be activated against recipient cells. KIR-ligand mismatch in the GVH direction improves outcomes after unrelated cord blood transplantation (UCBT) with acute myeloid leukemia, but the effect in T-ALL is unclear. We evaluated the impact of KIR-ligand mismatch in the GVH direction on the transplantation outcomes of children and adolescents with T-ALL who received UCBT. We conducted a retrospective study using a nationwide registry of the Japanese Society for Transplantation and Cellular Therapy. Patients diagnosed with T-ALL, aged 0 to 19 years, and who underwent first UCBT between 1999 and 2017 were included. A total of 91 patients were included in this study. In all, 23 (25.3%) percent of patients had KIR-ligand mismatch in the GVH direction. The 5-year leukemia-free survival (LFS) and overall survival (OS) rates after UCBT were 65.8% and 69.6%, respectively. In a multivariate analysis, KIR-ligand mismatch in the GVH direction was associated with a significant reduction in the relapse rate (hazard ratio [HR], 0.19; P = .002), resulting in better LFS (HR, 0.18; P =.010) and OS (HR, 0.26; P = .048) without increasing non-relapse mortality (NRM; HR, 1.90; P = .264). The cumulative incidence of GVH disease (GVHD) did not differ between patients with and without KIR-ligand mismatch (grade II-IV acute GVHD, 39.1% versus 36.8%, P = .648, grade III-IV acute GVHD, 13.0% versus 11.8%, P =.857, and chronic GVHD, 26.1% versus 22.9%, P =.736, respectively). Furthermore, acute and chronic GVHD were not associated with good patient outcomes. Notably, no relapse was observed in patients who received KIR-ligand mismatched UCBT in complete remission. KIR-ligand mismatch in the GVH direction improved LFS and decreased relapse rates without increasing NRM in children and adolescents with T-ALL who received UCBT, which was not mediated by GVHD.

DOI： 10.1016/j.jtct.2022.05.037

PubMed

researchmap

JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia 査読

Yoshihiro Takahashi, Hisashi Ishida, Toshihiko Imamura, Kosuke Tamefusa, Souichi Suenobu, Ikuya Usami, Keiko Yumura-Yagi, Daiichiro Hasegawa, Shinichiro Nishimura, Nobuhiro Suzuki, Yoshiko Hashii, Takao Deguchi, Akiko Moriya-Saito, Yoshiyuki Kosaka, Koji Kato, Ryoji Kobayashi, Hirohide Kawasaki, Hiroki Hori, Atsushi Sato, Toru Kudo, Tatsutoshi Nakahata, Megumi Oda, Junichi Hara, Keizo Horibe

International Journal of Hematology   115 ( 6 )   890 - 897   2022年6月

　詳細を見る

担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. As overall cure rates of childhood ALL have improved, reduction of overall treatment intensity while still ensuring excellent outcomes is imperative for low-risk patients. We report the outcomes of patients treated following the standard-risk protocol from the prospective Japan Association of Childhood Leukemia Study (JACLS) ALL-02 study, which was conducted between 2002 and 2008 for patients with newly diagnosed ALL aged 1-18 years. Of 1138 patients with B-cell precursor ALL, 388 (34.1%) were allocated to this protocol. Excellent outcomes were achieved despite the overall treatment intensity being lower than that of most contemporary protocols: 4 years event-free survival (EFS) was 92.3% and 4 years overall survival 98.2%. Patients with high hyperdiploidy (HHD) involving triple trisomy (trisomy of chromosomes 4, 10, and 17) or ETV6-RUNX1 had even better outcomes (4 years EFS 97.6% and 100%, respectively). Unique characteristics of this protocol include a selection of low-risk patients with a low initial WBC count and good early treatment response and reduction of cumulative doses of chemotherapeutic agents while maintaining dose density. In Japan, we are currently investigating the feasibility of this protocol while incorporating minimal residual disease into the patient stratification strategy.

DOI： 10.1007/s12185-022-03315-x

PubMed

researchmap

その他リンク： https://link.springer.com/article/10.1007/s12185-022-03315-x/fulltext.html

The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin‐Frankfurt‐Münster (BFM)95‐based protocol 査読 国際誌

Kunihiko Moriya, Toshihiko Imamura, Saori Katayama, Akira Kaino, Kenji Okamoto, Norihumi Yokoyama, Suguru Uemura, Hironobu Kitazawa, Masahiro Sekimizu, Hidefumi Hiramatsu, Ikuya Usami, Hisashi Ishida, Daiichiro Hasegawa, Asahito Hama, Akiko Moriya‐Saito, Atsushi Sato, Yoji Sasahara, Souichi Suenobu, Keizo Horibe, Junichi Hara

British Journal of Haematology   196 ( 5 )   1257 - 1261   2022年3月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

In this study, we performed a retrospective analysis of a cohort of Japanese paediatric patients with B-cell precursor (BCP)-acute lymphoblastic leukaemia (ALL) treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol, to clarify the incidence, clinical characteristics, and risk factors of osteonecrosis (ON) in comparison to the ALL-02 protocol. We identified a high frequency of ON with the BFM95-based protocol compared to the ALL-02 protocol. The incidence of symptomatic ON with the BFM95-based protocol is comparable to previous studies in Western countries. We believe that the type of treatment regimen has more impact on the incidence of symptomatic ON in paediatric ALL than ethnicity.

DOI： 10.1111/bjh.17988

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bjh.17988

Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study 査読

Hisashi Ishida, Mio Yano, Daiichiro Hasegawa, Tsukasa Hori, Yoshiko Hashii, Koji Kato, Takao Deguchi, Akiko Saito, Atsushi Sato, Hiroki Hori, Keizo Horibe, Toshihiko Imamura

International Journal of Hematology   113 ( 6 )   893 - 902   2021年2月

　詳細を見る

担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

Approximately 90% of pediatric acute lymphoblastic leukemia (ALL) cases are curable with intensified chemotherapy, but very high-risk patients may require hematopoietic stem cell transplantation (HSCT). A suitable indication for HSCT in the first complete remission (CR1) should be defined to protect patients from long-term complications. We report the outcomes of HSCT in CR1 from the Japan Association of Childhood Leukemia Study (JACLS) ALL-02 study and reassess indications for HSCT. Of 1114 patients, 71 (6.4%) received HSCT in CR1. Indications included high-risk cytogenetic abnormalities and non-CR on day 33. Patients with B-cell precursor (BCP) ALL and a prednisolone poor response (PPR) received HSCT when leukocyte antigen-matched siblings were available. The 4-year overall survival (OS) of transplanted patients was 78.8% (confidence interval 67.3-86.6). Multivariate analysis revealed that cord blood transplantation was associated with poor OS. For BCP-ALL patients with PPR who achieved CR1 after induction therapy, HSCT in CR1 showed excellent outcomes (4-year OS 90.9%) but demonstrated no survival advantage as the outcome with chemotherapy was also excellent (4-year OS 97.0%). This study suggests that in BCP-ALL patients PPR is not an indication for HSCT in CR1. Precise evaluation of treatment responses would increase sophistication of indications for HSCT in CR1.

DOI： 10.1007/s12185-021-03110-0

PubMed

researchmap

その他リンク： http://link.springer.com/article/10.1007/s12185-021-03110-0/fulltext.html

Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7 査読 国際誌

Masanori Yoshida, Kanako Tanase‐Nakao, Hirohito Shima, Ryota Shirai, Kaoru Yoshida, Tomoo Osumi, Takao Deguchi, Makiko Mori, Yuki Arakawa, Masatoshi Takagi, Takako Miyamura, Kimiyoshi Sakaguchi, Hidemi Toyoda, Hisashi Ishida, Naoki Sakata, Toshihiko Imamura, Yuta Kawahara, Akira Morimoto, Takashi Koike, Hiroshi Yagasaki, Shuichi Ito, Daisuke Tomizawa, Nobutaka Kiyokawa, Satoshi Narumi, Motohiro Kato

British Journal of Haematology   191 ( 5 )   835 - 843   2020年12月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

Monosomy 7 (-7) occurs in various types of paediatric myeloid disorders and has a poor prognosis. Recent studies have demonstrated that patients with germline gain-of-function SAMD9/9L variants and loss-of-function GATA2 variants are prone to developing myelodysplastic syndrome (MDS) associated with -7. However, the prevalence of the genetic variants among paediatric haematologic disorders with -7 is unknown. The present study screened germline variants of GATA2 and SAMD9/9L in 25 patients with various types of paediatric haematological disorders associated with -7. The diagnoses of the 25 patients included MDS (n = 10), acute myeloid leukaemia (AML) and myeloid sarcomas (n = 9), juvenile myelomonocytic leukaemia (n = 3) and other disorders (n = 3). Seven patients with a germline pathogenic GATA2 variant were found. For SAMD9/9L screening, next-generation sequencing was used to detect low-abundance variants and found four novel germline variants. Functional analysis revealed that three out of the four variants showed growth-restricting capacity in vitro and thus, were judged to be pathogenic. Cases with GATA2 mutation tended to be older, compared to those with SAMD9/9L mutations. In conclusion, GATA2 and SAMD9/9L were sequenced in 25 patients with paediatric haematologic disorders associated with -7, and 40% of them were found to have some pathogenic germline variants in the three genes.

DOI： 10.1111/bjh.17006

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bjh.17006

Clinical Factors Affecting the Dose Conversion Ratio from Intravenous to Oral Tacrolimus Formulation among Pediatric Hematopoietic Stem Cell Transplantation Recipients 査読

Kiichiro Kanamitsu, Takashi Yorifuji, Hisashi Ishida, Kaori Fujiwara, Kana Washio, Akira Shimada, Hirokazu Tsukahara

Therapeutic Drug Monitoring   42 ( 6 )   803 - 810   2020年12月

　詳細を見る

掲載種別：研究論文（学術雑誌）   出版者・発行元：Ovid Technologies (Wolters Kluwer Health)  

Background:

Tacrolimus is converted from intravenous to oral formulation for the prophylaxis of graft-versus-host disease when patients can tolerate oral intake and graft-versus-host disease is under control. Oral tacrolimus formulation presents poor bioavailability with intraindividual and interindividual variations; however, some factors affecting its blood concentration among pediatric hematopoietic stem cell transplantation (HCT) recipients are still unclear. This study aimed to identify the clinical factors affecting tacrolimus blood concentrations after switching its formulation.

Methods:

Changes in the blood concentration/dose ratio (C/D) of tacrolimus in pediatric HCT recipients were analyzed after the switching of tacrolimus from intravenous to oral formulation. Clinical records of 57 pediatric patients who underwent allogenic HCT from January 2006 to April 2019 in our institute were retrospectively reviewed. The C/D of tacrolimus before discontinuation of intravenous infusion (C/Div) was compared with the tacrolimus trough level within 10 days after the initiation of oral administration (C/Dpo). Multiple linear regression analysis was performed to identify factors affecting (C/Dpo)/(C/Div).

Results:

The constant coefficient of (C/Dpo)/(C/Div) was 0.1692 [95% confidence interval (CI), 0.137–0.2011]. The concomitant use of voriconazole or itraconazole and female sex were significant variables with a beta coefficient of 0.0974 (95% CI, 0.062–0.133) and −0.0373 (95% CI, −0.072 to −0.002), respectively.

Conclusions:

After switching of tacrolimus formulation, pediatric HCT recipients might need oral tacrolimus dose that is 5–6 and 3.5–4.5 times the intravenous dose to maintain tacrolimus blood concentrations and area under the concentration–time curve, respectively. With the concomitant use of voriconazole or itraconazole, an oral tacrolimus dose of 4–5 times the intravenous dose seemed appropriate to maintain blood tacrolimus concentration.

DOI： 10.1097/ftd.0000000000000793

PubMed

researchmap

Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance. 査読

Yasuhisa Tatebe, Kiichiro Kanamitsu, Hirotaka Kanzaki, Hisashi Ishida, Kaori Fujiwara, Kana Washio, Yoshihisa Kitamura, Toshiaki Sendo, Akira Shimada, Hirokazu Tsukahara

Acta medica Okayama   74 ( 6 )   545 - 550   2020年12月

　詳細を見る

記述言語：英語  

Polymorphisms in methotrexate transporter pathways have been associated with methotrexate toxicities and clearance. Recent genome-wide association studies have revealed that the SLCO1B1 T521C variant is associated with methotrexate elimination. We present a case of a pediatric patient with acute lymphoblastic leukemia who suffered from persistently high plasma methotrexate concentrations and acute kidney injuries after the admin-istration of a medium dose of methotrexate. Subsequent genetic analysis showed that he was a carrier of dys-functional genetic variants associated with methotrexate clearance. This case highlights that polymorphisms of methotrexate transporter pathways can adversely affect methotrexate elimination in a clinically significant manner.

DOI： 10.18926/AMO/61215

PubMed

researchmap

肝腫大によるoncologic emergencyを呈した神経芽腫の一例

尾山 貴徳, 野田 卓男, 谷 守通, 納所 洋, 谷本 光隆, 石田 悠志, 藤原 かおり, 金光 喜一郎, 鷲尾 佳奈, 嶋田 明

日本小児血液・がん学会雑誌   57 ( 3 )   327 - 327   2020年11月

　詳細を見る

記述言語：日本語   出版者・発行元：(一社)日本小児血液・がん学会  

researchmap

Panel‑based next‑generation sequencing facilitates the characterization of childhood acute myeloid leukemia in clinical settings

Hisashi Ishida, Akihiro Iguchi, Michinori Aoe, Ritsuo Nishiuchi, Takehiro Matsubara, Dai Keino, Masashi Sanada, Akira Shimada

Biomedical Reports   13 ( 5 )   1 - 1   2020年8月

　詳細を見る

掲載種別：研究論文（学術雑誌）   出版者・発行元：Spandidos Publications  

DOI： 10.3892/br.2020.1353

PubMed

researchmap

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey 査読 国際誌

Hisashi Ishida, Yuji Miyajima, Nobuyuki Hyakuna, Satoru Hamada, Takeo Sarashina, Risa Matsumura, Katsutsugu Umeda, Tetsuo Mitsui, Naoto Fujita, Daisuke Tomizawa, Kevin Y. Urayama, Yasushi Ishida, Takashi Taga, Masatoshi Takagi, Souichi Adachi, Atsushi Manabe, Toshihiko Imamura, Katsuyoshi Koh, Akira Shimada

eJHaem   1 ( 1 )   86 - 93   2020年7月

　詳細を見る

担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

Background: Philadelphia-negative (Ph-negative) myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are exceptionally rare during childhood. Thus, clinical features of pediatric Ph-negative MPNs remain largely unknown. This study was therefore performed to address this. Methods: We performed a retrospective study to collect clinical information of children diagnosed with Ph-negative MPNs from 2000 to 2016 using questionnaires in qualified institutions in Japan. The results obtained from the questionnaire survey were then combined with those from the national registry data. Results: Among 50 children identified, five had PV, 44 had ET, and one had PMF. Median age at diagnosis was 14.0, 9.0, and 0 years, respectively. Male to female ratio was 4:1, 21:23, and 1:0, respectively. Detection rates of the JAK2 V617F variant were 0/5 in PV and 9/39 in ET. Frequencies of complications, such as thrombosis and subsequent leukemia, were lower than complication frequencies in adults. We identified two children who developed subsequent leukemia, which has not been reported previously, and one of them died. Conclusion: This is the first nationally representative survey of pediatric Ph-negative MPNs. Given its rarity, an international collaboration with comprehensive genetic analyses might be needed to fully elucidate the clinical and genetic features.

DOI： 10.1002/jha2.39

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jha2.39

Severe acute intestinal graft versus host disease requiring surgical resection 査読 国際誌

Hisashi Ishida, Takuo Noda, Seiji Kawano, Maho Sato, Hirokazu Tsukahara, Akira Shimada

eJHaem   1 ( 1 )   328 - 329   2020年7月

　詳細を見る

担当区分：筆頭著者,　責任著者   記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1002/jha2.24

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jha2.24

A case of alveolar rhabdomyosarcoma showing concurrent responsive bone marrow lesions and refractory pancreatic lesions to pazopanib monotherapy 査読

Kiichiro Kanamitsu, Hisashi Ishida, Kaori Fujiwara, Kana Washio, Akira Shimada, Hirokazu Tsukahara

Pediatric Blood &amp; Cancer   67 ( 9 )   2020年5月

　詳細を見る

掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1002/pbc.28323

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/pbc.28323

Abdominal X‐ray showing magnetic attraction across the intestinal wall 査読

Hisashi Ishida, Machiko Miyamoto, Sachiko Yonezawa, Hitomi Matsuba, Yoichi Kondo

Pediatrics International   61 ( 10 )   1064 - 1064   2019年10月

　詳細を見る

担当区分：筆頭著者,　責任著者   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1111/ped.13977

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/ped.13977

キメラスクリーニングによる小児急性巨核芽球性白血病の予後解析 査読

Tamefusa K, Fukutake K, Ishida H, Tamura A, Endo M, Hamamoto K, Koga Y, Yamada M, Kanamitsu K, Fujiwara K, Washio K, Shimada A

臨床血液   60 ( 2 )   2019年2月

　詳細を見る

記述言語：日本語   掲載種別：研究論文（学術雑誌）  

DOI： 10.11406/rinketsu.60.99

J-GLOBAL

researchmap

Selective laser trabeculoplasty for steroid glaucoma in a child with leukemia 査読

Hisashi Ishida, Ryoichi Araki, Takashi Iwase, Tomoko Naito, Akira Shimada

Pediatrics International   61 ( 2 )   208 - 210   2019年2月

　詳細を見る

担当区分：筆頭著者   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1111/ped.13754

PubMed

researchmap

Remission of Congenital Multi-system Type Langerhans Cell Histiocytosis with Chemotherapy. 査読

Kosuke Tamefusa, Hisashi Ishida, Kana Washio, Toshiaki Ishida, Hirosuke Morita, Akira Shimada

Acta medica Okayama   73 ( 1 )   61 - 65   2019年2月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Patients with multi-system (MS)-type langerhans cell histiocytosis (LCH) show poor outcomes, especially congenital MS LCH cases were shown in high mortality rate. We experienced a congenital case of MS LCH with high risk organs, who needed intensive respiratory support after birth. Even though intensive chemotherapy was discontinued, this patient's lung LCH lesions gradually became reduced and his respiratory condition recovered; therefore, we restarted and completed maintenance chemotherapy. The patient maintained complete remission for more than 4 years after the end of chemotherapy. Our case suggests that congenital MS LCH even with severe organ involvement can be treated successfully with chemotherapy.

DOI： 10.18926/AMO/56459

PubMed

researchmap

Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing 査読

Hisashi Ishida, Akihiro Iguchi, Michinori Aoe, Takahide Takahashi, Kosuke Tamefusa, Kiichiro Kanamitsu, Kaori Fujiwara, Kana Washio, Takehiro Matsubara, Hirokazu Tsukahara, Masashi Sanada, Akira Shimada

Annals of Hematology   98 ( 3 )   657 - 668   2018年11月

　詳細を見る

担当区分：筆頭著者   掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

DOI： 10.1007/s00277-018-3554-8

PubMed

researchmap

その他リンク： http://link.springer.com/content/pdf/10.1007/s00277-018-3554-8.pdf

Wernicke's encephalopathy in a child with autism during chemotherapy for T‐cell acute leukemia 査読

Kazumasa Zensho, Hisashi Ishida, Hiroki Nagai, Hirokazu Tsukahara, Akira Shimada

Pediatrics International   60 ( 8 )   757 - 758   2018年8月

　詳細を見る

掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1111/ped.13615

PubMed

researchmap

Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel 査読 国際誌

M. Aoe, H. Ishida, T. Matsubara, S. Karakawa, H. Kawaguchi, K. Fujiwara, K. Kanamitsu, K. Washio, K. Okada, M. Shibakura, A. Shimada

International Journal of Laboratory Hematology   40 ( 4 )   427 - 436   2018年8月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

INTRODUCTION: Recent clinical outcomes of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) vastly improved owing to tyrosine kinase inhibitor (TKI). However, the genetic status would be different in each case with ABL1 gene mutation or copy number variants (CNVs) such as IKZF1 deletion. In particular, the TKI resistant clone with ABL1 kinase mutation remains problematic. The comprehensive assessment of genetic status including mutation, insertion and deletion (indel) and CNVs is necessary. METHODS: We evaluated a next-generation sequencing (NGS)-based customized HaloPlex target enrichment system panel to simultaneously detect coding mutations, indel and CNVs. We analysed approximately 160 known genes associated with hematological disorders in 5 pediatric Ph+ALL patients. RESULTS: Mono-allelic IKZF1 deletions were found in 4 patients at diagnosis. Furthermore, the mono-allelic deletions were found in exons of RB1, EBF1, PAX5 and ETV6 genes. Bi-allelic deletions were detected in CDKN2A and CDKN2B genes in 1 patient. ABL1 mutation was also detected in 1 patient at relapse. These results were almost comparable with the results of the multiplex ligation-dependent probe amplification (MLPA) method or Sanger sequence. CONCLUSION: Next-generation sequencing-based custom HaloPlex target enrichment system panel allows us to detect the coding mutations, indel, and CNVs in pediatric Ph+ALL simultaneously, and its results seem comparable with those of other methods.

DOI： 10.1111/ijlh.12805

PubMed

researchmap

Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group 査読

Kenichi Sakamoto, Toshihiko Imamura, Kentaro Kihira, Koji Suzuki, Hisashi Ishida, Hiromi Morita, Miyako Kanno, Takeshi Mori, Hidefumi Hiramatsu, Kousaku Matsubara, Kiminori Terui, Yoshihiro Takahashi, So-ichi Suenobu, Daiichiro Hasegawa, Yoshiyuki Kosaka, Koji Kato, Akiko Moriya-Saito, Atsushi Sato, Hirohide Kawasaki, Keiko Yumura-Yagi, Junichi Hara, Hiroki Hori, Keizo Horibe

Journal of Clinical Oncology   36 ( 9 )   900 - 907   2018年3月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1200/jco.2017.75.5066

Web of Science

PubMed

researchmap

腎生検にて確定診断に至った移植関連血栓性微小血管障害 査読

宮本智史, 宮本智史, 木村俊介, 細谷要介, 長谷川大輔, 石田悠志, 代田惇朗, 松井俊大, 吉本優里, 平林真介, 藤丸拓也, 熊本忠史, 森慎一郎, 鈴木高祐, 真部淳

臨床血液   59 ( 4 )   2018年1月

　詳細を見る

掲載種別：研究論文（学術雑誌）  

DOI： 10.11406/rinketsu.59.389

PubMed

J-GLOBAL

researchmap

多発肺転移を伴う甲状腺乳頭癌の自閉症児例

尾山 貴徳, 野田 卓男, 谷 守通, 納所 洋, 谷本 光隆, 岩本 貴行, 元木 崇之, 樋口 洋介, 藤原 かおり, 石田 悠志, 金光 喜一郎, 鷲尾 佳奈, 嶋田 明

日本小児血液・がん学会雑誌   54 ( 3 )   275 - 275   2017年12月

　詳細を見る

記述言語：日本語   出版者・発行元：(一社)日本小児血液・がん学会  

researchmap

Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report 査読

Yousuke Higuchi, Takayuki Motoki, Hisashi Ishida, Kiichiro Kanamitsu, Kana Washio, Takanori Oyama, Takuo Noda, Yasuko Tsurumaru, Ayumi Okada, Hirokazu Tsukahara, Akira Shimada

BMC Cancer   17 ( 1 )   2017年11月

　詳細を見る

掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

DOI： 10.1186/s12885-017-3782-7

PubMed

researchmap

多彩な合併症を呈するBeckwith-Wiedemann症候群に発症した乳児肝芽腫の一例

尾山 貴徳, 野田 卓男, 谷 守通, 納所 洋, 谷本 光隆, 谷 和祐, 石田 悠志, 岡村 朋香, 藤原 かおり, 金光 喜一郎, 鷲尾 洋介, 鷲尾 佳奈, 吉本 順子, 嶋田 明

日本小児血液・がん学会雑誌   54 ( 4 )   333 - 333   2017年10月

　詳細を見る

記述言語：日本語   出版者・発行元：(一社)日本小児血液・がん学会  

researchmap

Desmoid‐type fibromatosis in a boy with Down syndrome 査読

Hisashi Ishida, Kousuke Chayama, Kiichiro Kanamitsu, Kana Washio, Takehiro Tanaka, Akira Shimada

Pediatrics International   59 ( 5 )   624 - 626   2017年4月

　詳細を見る

担当区分：筆頭著者   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

Abstract

Patients with Down syndrome (DS) have a markedly higher incidence of childhood leukemia, but a lower incidence of most solid tumors, compared with age‐matched euploid individuals. Trisomy 21 might be protective against tumorigenesis because of several tumor suppressive mechanisms. Desmoid‐type fibromatosis (DF) is a rare monoclonal, fibroblastic proliferation characterized by a variable clinical course. In recent reports, almost all cases of DF involved genomic alterations associated with activation of the Wnt/β‐catenin pathway. Here, we report the case of a boy with DS who developed DF without activation of the Wnt/β‐catenin pathway. To the best of our knowledge, this is the first case of DS involving DF.

DOI： 10.1111/ped.13241

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/ped.13241

Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis 査読

Kanazawa Yui, Yamashita Yuka, Fujiwara Mitsuhiro, Muraoka Michiko, Washio Kana, Kanamitsu Kiichiro, Ishida Hisashi, Nakano Takae, Yamada Miho, Horibe Keizo, Tanaka Takehiro, Yoshino Tadashi, Shimada Akira

Acta Medica Okayama   70 ( 6 )   503 - 506   2016年12月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Okayama University Medical School  

Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10–30 of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60–75 disease-free survival; however, a relatively high relapse rate was observed (25–30 ). We report 2 patients with Stage III ALCL who relapsed 6–18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be relatively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneficial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the first diagnostic bone marrow sample.

DOI： 10.18926/AMO/54815

PubMed

CiNii Article

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2017326192

MIBG陰性神経芽腫に対するFDG-PETの有用性(Value of FDG-PET for the assessment of treatment efficacy in MIBG-negative neuroblastoma patients)

尾山 貴徳, 野田 卓男, 谷 守通, 納所 洋, 谷本 光隆, 藤原 かおり, 石田 悠志, 金光 喜一郎, 鷲尾 佳奈, 嶋田 明

日本小児血液・がん学会雑誌   53 ( 4 )   231 - 231   2016年11月

　詳細を見る

記述言語：英語   出版者・発行元：(一社)日本小児血液・がん学会  

researchmap

化学療法を行った先天性全身型黄色肉芽腫症の一例(A case of congenital systemic juvenile xanthogranuloma treated with chemotherapy)

金光 喜一郎, 石田 悠志, 藤原 かおり, 鷲尾 佳奈, 田中 健大, 嶋田 明

日本小児血液・がん学会雑誌   53 ( 4 )   245 - 245   2016年11月

　詳細を見る

記述言語：英語   出版者・発行元：(一社)日本小児血液・がん学会  

researchmap

Relapsed infant MLL‐rearranged acute lymphoblastic leukemia with additional genetic alterations 査読

Hisashi Ishida, Kiichiro Kanamitsu, Kana Washio, Michiko Muraoka, Kanae Sakakibara, Takehiro Matsubara, Hirotaka Kanzaki, Akira Shimada

Pediatric Blood &amp; Cancer   63 ( 11 )   2059 - 2060   2016年6月

　詳細を見る

担当区分：筆頭著者   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1002/pbc.26100

PubMed

researchmap

Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy 査読

Muraoka Michiko, Okuma Chiho, Kanamitsu Kiichiro, Ishida Hisashi, Kanazawa Yui, Washio Kana, Seki Masafumi, Kato Motohiro, Takita Junko, Sato Yusuke, Ogawa Seishi, Tsukahara Hirokazu, Oda Megumi, Shimada Akira

Journal of human genetics   61 ( 6 )   523 - 526   2016年6月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Nature Publishing Group  

DOI： 10.1038/jhg.2016.8

CiNii Article

CiNii Books

researchmap

その他リンク： http://www.nature.com/articles/jhg20168

小児最重症再生不良性貧血に対する非血縁者間臍帯血移植

木村 俊介, 長谷川 大輔, 松井 俊大, 代田 惇朗, 石田 悠志, 吉本 優里, 平林 真介, 細谷 要介, 吉原 宏樹, 熊本 忠史, 森 愼一郎, 真部 淳

日本小児血液・がん学会雑誌   53 ( 1 )   21 - 25   2016年4月

　詳細を見る

記述言語：日本語   出版者・発行元：(一社)日本小児血液・がん学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2016&ichushi_jid=J06030&link_issn=&doc_id=20160829280005&doc_link_id=%2Fex9syoga%2F2016%2F005301%2F005%2F0021-0025%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fex9syoga%2F2016%2F005301%2F005%2F0021-0025%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

小児固形腫瘍におけるFDG-PET/CTの有用性の検討(Usefulness of FDG-PET/CT for pediatric solid tumor)

納所 洋, 野田 卓男, 尾山 貴徳, 谷本 光隆, 嶋田 明, 鷲尾 佳奈, 金光 喜一郎, 石田 悠志

日本小児血液・がん学会雑誌   52 ( 4 )   336 - 336   2015年10月

　詳細を見る

記述言語：英語   出版者・発行元：(一社)日本小児血液・がん学会  

researchmap

免疫異常 骨髄異形成症候群と大腸多発癌を合併した先天性角化不全症の1例(Immune disorder A case of dyskeratosis congenita developed myelodysplastic syndrome and multiple colon cancer)

尾山 貴徳, 野田 卓男, 納所 洋, 谷本 光隆, 石田 悠志, 金光 喜一郎, 鷲尾 佳奈, 長谷川 高誠, 田中 弘之, 神崎 洋光, 永坂 岳司, 嶋田 明

日本小児血液・がん学会雑誌   52 ( 4 )   214 - 214   2015年10月

　詳細を見る

記述言語：英語   出版者・発行元：(一社)日本小児血液・がん学会  

researchmap

胎生期早期の発生が疑われたランゲルハンス組織球症の1例(Suspected early onset of congenital Langerhans cell histiocytosis involving ectopic cervical thymus and mediastinal thymus, simultaneously)

金光 喜一郎, 石田 悠志, 鷲尾 佳奈, 小田 慈, 野田 卓男, 尾山 貴徳, 谷本 光隆, 田中 健大, 井田 健太郎, 嶋田 明

日本小児血液・がん学会雑誌   52 ( 4 )   236 - 236   2015年10月

　詳細を見る

記述言語：英語   出版者・発行元：(一社)日本小児血液・がん学会  

researchmap

消化管出血を伴う青色ゴムまり様母斑症候群の乳児例(An infant of blue rubber bleb nevus syndrome with gastrointestinal bleeding)

平林 真介, 栗山 絢子, 石田 悠志, 吉本 優里, 細谷 要介, 吉原 宏樹, 川野 孝文, 迫田 晃子, 森田 有香, 中村 仁美, 衛藤 光, 鈴木 高祐, 末延 聡一, 長谷川 大輔, 真部 淳

日本小児血液・がん学会雑誌   51 ( 4 )   242 - 242   2014年10月

　詳細を見る

記述言語：英語   出版者・発行元：(一社)日本小児血液・がん学会  

researchmap